SurfingMASH concludes its coverage of the Emerging Trends Conference looking at an encouraging future in MASLD drug development and increasing interest in patient advocacy.
This week’s expert interview with Jeff McIntyre of the Global Liver Institute took place one day after news media reported on high-level job cuts at FDA. Jeff and Roger discuss possible implications for MASH drug and diagnostic development and the steps patients can take to protect their rights and health.
This week’s Newsmaker is Yukti Choudhury of HistoIndex, discussing FibroSIGHT, the company’s new diagnostic for use in clinical practices.
This week’s Roundtable segment focuses on what we can learn from today’s trial results about trends for the future and asks questions about ALD trial design.
SurfingMASH explores the future evolution of drug therapy, a new biopsy-enhancing option for clinical use and the implications of FDA and NIH job cuts.
SurfingMASH covers two major February conferences: the AASLD Emerging Trends Conference and the Desert Liver Conference, with similar multispecialty perspectives on the entire range of steatotic liver diseases, while Jörn Schattenberg discusses how his practice (and all of Europe) is preparing for resmetirom.
This final conversation focuses on conference presentations on Determinants of MASH Health and the Healthy Livers, Healthy Lives program, and what panelists anticipate for #TLM2025.
This conversation focuses on two patient-related issues: the importance of patient advocacy in removing biopsy from clinical trial designs and more generally, principles for patient-centric clinical trials.
This conversation covers the likely role of FGF-21 agents in future MASH therapy and discusses positive messages from the “FDA Corner” session.
This conversation starts by asking whether approval of two drugs for use without biopsy will challenge MASH trial recruitment and goes on to look at recent studies discussing patient genotyping and clustering.
